Governance - LyonbiopôleLyonbiopôle, pôle de compétitivité mondial en santé

Lyonbiopole Governance

Headlines

GeNeuro’s ANGEL-MS Phase 2b study confirms and extends the neuroprotective effects of temelimab in MS

March 13^th, 2019

Theranexus announces preliminary results of phase II trial of THN102

February 28^th, 2019

PDC*line Pharma enters into a licensing agreement with LG Chem to develop cancer vaccine

March 21^th, 2019

Diary

Lyonbiopole General Assembly

May 21^th, 2019

China-Singapore Mission

May 6^th, 2019

BIO International Convention 2019

June 3^th, 2019

Calls for projects

SME Instrument (phase 2)

Before April 3^th, 2019

All calls for projects

Contact

Bâtiment Domilyon - 321, avenue Jean Jaurès - 69007 Lyon

Tel. : 04.72.76.53.30 - Fax : 09.55.91.30.26

info@lyonbiopole.com

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close